Approval · Notice of Compliance 31320 · 2023
AXBERI: Notice of Compliance 31320
Issued July 27, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 31320
- Date
- July 27, 2023
- Company
- Baxter CorporationMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- Other
- Canadian reference product
- LOVENOX / LOVENOX HP
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| AXBERI | Not yet assigned | — |
| AXBERI HP | Not yet assigned | — |
Medicinal ingredients
- ENOXAPARIN SODIUM 30 MG per PEN
- ENOXAPARIN SODIUM 40 MG per PEN
- ENOXAPARIN SODIUM 60 MG per PEN
- ENOXAPARIN SODIUM 80 MG per PEN
- ENOXAPARIN SODIUM 100 MG per PEN
- ENOXAPARIN SODIUM 120 MG per PEN
- ENOXAPARIN SODIUM 150 MG per PEN